Global Tourette Syndrome Drug Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Tourette Syndrome Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Tourette Syndrome Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Tourette Syndrome Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Tourette Syndrome Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Tourette Syndrome Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Tourette Syndrome Drug market include Teva Pharmaceutical Industries Ltd, Therapix Biosciences Ltd, Synchroneuron Inc, Reviva Pharmaceuticals Inc, Psyadon Pharmaceuticals Inc, Neurocrine Biosciences Inc, Catalyst Pharmaceuticals Inc and Abide Therapeutics Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Tourette Syndrome Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Tourette Syndrome Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Tourette Syndrome Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Tourette Syndrome Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Tourette Syndrome Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Tourette Syndrome Drug sales, projected growth trends, production technology, application and end-user industry.
Tourette Syndrome Drug Segment by Company
Teva Pharmaceutical Industries Ltd
Therapix Biosciences Ltd
Synchroneuron Inc
Reviva Pharmaceuticals Inc
Psyadon Pharmaceuticals Inc
Neurocrine Biosciences Inc
Catalyst Pharmaceuticals Inc
Abide Therapeutics Inc
Tourette Syndrome Drug Segment by Type
Ecopipam Hydrochloride
Dutetrabenazine ER
CPP-115
AZD-5213
Others
Tourette Syndrome Drug Segment by Application
Clinic
Hospital
Research Center
Others
Tourette Syndrome Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Tourette Syndrome Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Tourette Syndrome Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Tourette Syndrome Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Tourette Syndrome Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tourette Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tourette Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tourette Syndrome Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Tourette Syndrome Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tourette Syndrome Drug industry.
Chapter 3: Detailed analysis of Tourette Syndrome Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Tourette Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Tourette Syndrome Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Tourette Syndrome Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Tourette Syndrome Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Tourette Syndrome Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Tourette Syndrome Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Tourette Syndrome Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Tourette Syndrome Drug market include Teva Pharmaceutical Industries Ltd, Therapix Biosciences Ltd, Synchroneuron Inc, Reviva Pharmaceuticals Inc, Psyadon Pharmaceuticals Inc, Neurocrine Biosciences Inc, Catalyst Pharmaceuticals Inc and Abide Therapeutics Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Tourette Syndrome Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Tourette Syndrome Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Tourette Syndrome Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Tourette Syndrome Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Tourette Syndrome Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Tourette Syndrome Drug sales, projected growth trends, production technology, application and end-user industry.
Tourette Syndrome Drug Segment by Company
Teva Pharmaceutical Industries Ltd
Therapix Biosciences Ltd
Synchroneuron Inc
Reviva Pharmaceuticals Inc
Psyadon Pharmaceuticals Inc
Neurocrine Biosciences Inc
Catalyst Pharmaceuticals Inc
Abide Therapeutics Inc
Tourette Syndrome Drug Segment by Type
Ecopipam Hydrochloride
Dutetrabenazine ER
CPP-115
AZD-5213
Others
Tourette Syndrome Drug Segment by Application
Clinic
Hospital
Research Center
Others
Tourette Syndrome Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Tourette Syndrome Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Tourette Syndrome Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Tourette Syndrome Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Tourette Syndrome Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tourette Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tourette Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tourette Syndrome Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Tourette Syndrome Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tourette Syndrome Drug industry.
Chapter 3: Detailed analysis of Tourette Syndrome Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Tourette Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Tourette Syndrome Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
199 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Tourette Syndrome Drug Sales Value (2020-2031)
- 1.2.2 Global Tourette Syndrome Drug Sales Volume (2020-2031)
- 1.2.3 Global Tourette Syndrome Drug Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Tourette Syndrome Drug Market Dynamics
- 2.1 Tourette Syndrome Drug Industry Trends
- 2.2 Tourette Syndrome Drug Industry Drivers
- 2.3 Tourette Syndrome Drug Industry Opportunities and Challenges
- 2.4 Tourette Syndrome Drug Industry Restraints
- 3 Tourette Syndrome Drug Market by Company
- 3.1 Global Tourette Syndrome Drug Company Revenue Ranking in 2024
- 3.2 Global Tourette Syndrome Drug Revenue by Company (2020-2025)
- 3.3 Global Tourette Syndrome Drug Sales Volume by Company (2020-2025)
- 3.4 Global Tourette Syndrome Drug Average Price by Company (2020-2025)
- 3.5 Global Tourette Syndrome Drug Company Ranking (2023-2025)
- 3.6 Global Tourette Syndrome Drug Company Manufacturing Base and Headquarters
- 3.7 Global Tourette Syndrome Drug Company Product Type and Application
- 3.8 Global Tourette Syndrome Drug Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Tourette Syndrome Drug Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Tourette Syndrome Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Tourette Syndrome Drug Market by Type
- 4.1 Tourette Syndrome Drug Type Introduction
- 4.1.1 Ecopipam Hydrochloride
- 4.1.2 Dutetrabenazine ER
- 4.1.3 CPP-115
- 4.1.4 AZD-5213
- 4.1.5 Others
- 4.2 Global Tourette Syndrome Drug Sales Volume by Type
- 4.2.1 Global Tourette Syndrome Drug Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Tourette Syndrome Drug Sales Volume by Type (2020-2031)
- 4.2.3 Global Tourette Syndrome Drug Sales Volume Share by Type (2020-2031)
- 4.3 Global Tourette Syndrome Drug Sales Value by Type
- 4.3.1 Global Tourette Syndrome Drug Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Tourette Syndrome Drug Sales Value by Type (2020-2031)
- 4.3.3 Global Tourette Syndrome Drug Sales Value Share by Type (2020-2031)
- 5 Tourette Syndrome Drug Market by Application
- 5.1 Tourette Syndrome Drug Application Introduction
- 5.1.1 Clinic
- 5.1.2 Hospital
- 5.1.3 Research Center
- 5.1.4 Others
- 5.2 Global Tourette Syndrome Drug Sales Volume by Application
- 5.2.1 Global Tourette Syndrome Drug Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Tourette Syndrome Drug Sales Volume by Application (2020-2031)
- 5.2.3 Global Tourette Syndrome Drug Sales Volume Share by Application (2020-2031)
- 5.3 Global Tourette Syndrome Drug Sales Value by Application
- 5.3.1 Global Tourette Syndrome Drug Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Tourette Syndrome Drug Sales Value by Application (2020-2031)
- 5.3.3 Global Tourette Syndrome Drug Sales Value Share by Application (2020-2031)
- 6 Tourette Syndrome Drug Regional Sales and Value Analysis
- 6.1 Global Tourette Syndrome Drug Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Tourette Syndrome Drug Sales by Region (2020-2031)
- 6.2.1 Global Tourette Syndrome Drug Sales by Region: 2020-2025
- 6.2.2 Global Tourette Syndrome Drug Sales by Region (2026-2031)
- 6.3 Global Tourette Syndrome Drug Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Tourette Syndrome Drug Sales Value by Region (2020-2031)
- 6.4.1 Global Tourette Syndrome Drug Sales Value by Region: 2020-2025
- 6.4.2 Global Tourette Syndrome Drug Sales Value by Region (2026-2031)
- 6.5 Global Tourette Syndrome Drug Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Tourette Syndrome Drug Sales Value (2020-2031)
- 6.6.2 North America Tourette Syndrome Drug Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Tourette Syndrome Drug Sales Value (2020-2031)
- 6.7.2 Europe Tourette Syndrome Drug Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Tourette Syndrome Drug Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Tourette Syndrome Drug Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Tourette Syndrome Drug Sales Value (2020-2031)
- 6.9.2 South America Tourette Syndrome Drug Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Tourette Syndrome Drug Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Tourette Syndrome Drug Sales Value Share by Country, 2024 VS 2031
- 7 Tourette Syndrome Drug Country-level Sales and Value Analysis
- 7.1 Global Tourette Syndrome Drug Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Tourette Syndrome Drug Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Tourette Syndrome Drug Sales by Country (2020-2031)
- 7.3.1 Global Tourette Syndrome Drug Sales by Country (2020-2025)
- 7.3.2 Global Tourette Syndrome Drug Sales by Country (2026-2031)
- 7.4 Global Tourette Syndrome Drug Sales Value by Country (2020-2031)
- 7.4.1 Global Tourette Syndrome Drug Sales Value by Country (2020-2025)
- 7.4.2 Global Tourette Syndrome Drug Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.9.2 France Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.16.2 China Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.19.2 India Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Tourette Syndrome Drug Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Tourette Syndrome Drug Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Tourette Syndrome Drug Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Teva Pharmaceutical Industries Ltd
- 8.1.1 Teva Pharmaceutical Industries Ltd Comapny Information
- 8.1.2 Teva Pharmaceutical Industries Ltd Business Overview
- 8.1.3 Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Product Portfolio
- 8.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 8.2 Therapix Biosciences Ltd
- 8.2.1 Therapix Biosciences Ltd Comapny Information
- 8.2.2 Therapix Biosciences Ltd Business Overview
- 8.2.3 Therapix Biosciences Ltd Tourette Syndrome Drug Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Therapix Biosciences Ltd Tourette Syndrome Drug Product Portfolio
- 8.2.5 Therapix Biosciences Ltd Recent Developments
- 8.3 Synchroneuron Inc
- 8.3.1 Synchroneuron Inc Comapny Information
- 8.3.2 Synchroneuron Inc Business Overview
- 8.3.3 Synchroneuron Inc Tourette Syndrome Drug Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Synchroneuron Inc Tourette Syndrome Drug Product Portfolio
- 8.3.5 Synchroneuron Inc Recent Developments
- 8.4 Reviva Pharmaceuticals Inc
- 8.4.1 Reviva Pharmaceuticals Inc Comapny Information
- 8.4.2 Reviva Pharmaceuticals Inc Business Overview
- 8.4.3 Reviva Pharmaceuticals Inc Tourette Syndrome Drug Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Reviva Pharmaceuticals Inc Tourette Syndrome Drug Product Portfolio
- 8.4.5 Reviva Pharmaceuticals Inc Recent Developments
- 8.5 Psyadon Pharmaceuticals Inc
- 8.5.1 Psyadon Pharmaceuticals Inc Comapny Information
- 8.5.2 Psyadon Pharmaceuticals Inc Business Overview
- 8.5.3 Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Product Portfolio
- 8.5.5 Psyadon Pharmaceuticals Inc Recent Developments
- 8.6 Neurocrine Biosciences Inc
- 8.6.1 Neurocrine Biosciences Inc Comapny Information
- 8.6.2 Neurocrine Biosciences Inc Business Overview
- 8.6.3 Neurocrine Biosciences Inc Tourette Syndrome Drug Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Neurocrine Biosciences Inc Tourette Syndrome Drug Product Portfolio
- 8.6.5 Neurocrine Biosciences Inc Recent Developments
- 8.7 Catalyst Pharmaceuticals Inc
- 8.7.1 Catalyst Pharmaceuticals Inc Comapny Information
- 8.7.2 Catalyst Pharmaceuticals Inc Business Overview
- 8.7.3 Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Product Portfolio
- 8.7.5 Catalyst Pharmaceuticals Inc Recent Developments
- 8.8 Abide Therapeutics Inc
- 8.8.1 Abide Therapeutics Inc Comapny Information
- 8.8.2 Abide Therapeutics Inc Business Overview
- 8.8.3 Abide Therapeutics Inc Tourette Syndrome Drug Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Abide Therapeutics Inc Tourette Syndrome Drug Product Portfolio
- 8.8.5 Abide Therapeutics Inc Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Tourette Syndrome Drug Value Chain Analysis
- 9.1.1 Tourette Syndrome Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Tourette Syndrome Drug Sales Mode & Process
- 9.2 Tourette Syndrome Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Tourette Syndrome Drug Distributors
- 9.2.3 Tourette Syndrome Drug Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
